Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
524 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01777243 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01101542 | Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females | completed | — | 3,091 | GlaxoSmithKlineINDUSTRY | 1 | Jul 23, 2018 | clinicaltrials |
| NCT00344032 | Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women | completed | Phase 3 | 354 | GlaxoSmithKlineINDUSTRY | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00345878 | Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years | completed | Phase 3 | 271 | GlaxoSmithKlineINDUSTRY | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00369824 | Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects | completed | Phase 3 | 1,330 | GlaxoSmithKlineINDUSTRY | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00426361 | Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects | completed | Phase 3 | 751 | GlaxoSmithKlineINDUSTRY | 3 | Jul 20, 2018 | clinicaltrials |
| NCT00485732 | A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years | completed | Phase 3 | 225 | GlaxoSmithKlineINDUSTRY | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00549900 | A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00504790 | Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer | completed | Phase 1 | 39 | GlaxoSmithKlineINDUSTRY | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00799825 | Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US | completed | Phase 3 | 346 | GlaxoSmithKlineINDUSTRY | 2 | Jul 12, 2018 | clinicaltrials |
| NCT01418937 | Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study | completed | Phase 3 | 164 | GlaxoSmithKlineINDUSTRY | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00546078 | Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America | completed | Phase 2 | 116 | GlaxoSmithKlineINDUSTRY | 2 | Jun 26, 2018 | clinicaltrials |
| NCT00552279 | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age | completed | Phase 3 | 805 | GlaxoSmithKlineINDUSTRY | 3 | Jun 25, 2018 | clinicaltrials |
| NCT01248897 | Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib(BioPATH) | completed | — | 158 | GlaxoSmithKlineINDUSTRY | 4 | Jun 19, 2018 | clinicaltrials |
| NCT01462604 | Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast Cancer | completed | — | 27 | GlaxoSmithKlineINDUSTRY | 4 | Jun 19, 2018 | clinicaltrials |
| NCT01159964 | Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery | terminated | Phase 1 | 60 | GlaxoSmithKlineINDUSTRY | 6 | Jun 18, 2018 | clinicaltrials |
| NCT01767467 | Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers | completed | Phase 3 | 568 | GlaxoSmithKlineINDUSTRY | 21 | Jun 6, 2018 | clinicaltrials |
| NCT02065063 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors | completed | Phase 1 | 28 | GlaxoSmithKlineINDUSTRY | 1 | Jun 1, 2018 | clinicaltrials |
| NCT01245062 | GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma | completed | Phase 3 | 322 | GlaxoSmithKlineINDUSTRY | 19 | Apr 5, 2018 | clinicaltrials |
| NCT00089973 | Study Of Ispinesib In Subjects With Breast Cancer | completed | Phase 2 | 50 | GlaxoSmithKlineINDUSTRY | 5 | Feb 26, 2018 | clinicaltrials |
| NCT00455923 | SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII) | completed | Phase 4 | 100 | GlaxoSmithKlineINDUSTRY | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00706199 | The Expression of Antigens in Bone Marrow Samples From Volunteering Donors. | completed | — | 48 | GlaxoSmithKlineINDUSTRY | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00601172 | A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. | completed | Phase 3 | 710 | GlaxoSmithKlineINDUSTRY | 11 | Jan 17, 2018 | clinicaltrials |
| NCT00615524 | Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Jan 12, 2018 | clinicaltrials |
| NCT00536809 | Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer | completed | Phase 1 | 12 | GlaxoSmithKlineINDUSTRY | 1 | Dec 18, 2017 | clinicaltrials |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 12, 2017 | clinicaltrials |
| NCT00726323 | A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) | completed | Phase 2 | 74 | GlaxoSmithKlineINDUSTRY | 1 | Dec 11, 2017 | clinicaltrials |
| NCT03266159 | A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 8, 2017 | clinicaltrials |
| NCT00148902 | Effects Of GW572016 In Combination With Docetaxel (TAXOTERE) | completed | Phase 1 | 52 | GlaxoSmithKlineINDUSTRY | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00258050 | To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients | completed | Phase 1 | 24 | GlaxoSmithKlineINDUSTRY | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00540943 | Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00158782 | Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients | completed | Phase 1 | 75 | GlaxoSmithKlineINDUSTRY | 2 | Nov 17, 2017 | clinicaltrials |
| NCT00169533 | Rollover Study Of Lapatinib In Cancer Patients | completed | Phase 1 | 31 | GlaxoSmithKlineINDUSTRY | 3 | Nov 17, 2017 | clinicaltrials |
| NCT00334646 | Cyclophosphamide Drug Interaction Study In Cancer Patients | terminated | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 3 | Nov 17, 2017 | clinicaltrials |
| NCT00361803 | Topotecan Pharmacokinetic Characterization Study | completed | Phase 1 | 15 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00363194 | A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients | completed | Phase 1 | 28 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00370513 | A Phase I Study of Pazopanib in Adult Patients With Liver Cancer | completed | Phase 1 | 28 | GlaxoSmithKlineINDUSTRY | 3 | Nov 17, 2017 | clinicaltrials |
| NCT00387387 | Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin) | completed | Phase 1 | 50 | GlaxoSmithKlineINDUSTRY | 2 | Nov 17, 2017 | clinicaltrials |
| NCT00388076 | Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) | completed | Phase 1 | 86 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00478725 | Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034 | completed | Phase 1 | 10 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00528281 | A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 4 | Nov 17, 2017 | clinicaltrials |
| NCT00619424 | A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors | completed | Phase 1 | 58 | GlaxoSmithKlineINDUSTRY | 2 | Nov 17, 2017 | clinicaltrials |
| NCT00650910 | Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer | completed | Phase 1 | 17 | GlaxoSmithKlineINDUSTRY | 3 | Nov 17, 2017 | clinicaltrials |
| NCT00742144 | Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 6 | GlaxoSmithKlineINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00158886 | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer | terminated | Phase 1 | 26 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00259935 | A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors | completed | Phase 1 | 107 | GlaxoSmithKlineINDUSTRY | 2 | Nov 14, 2017 | clinicaltrials |
| NCT00678977 | A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors | completed | Phase 1 | 22 | GlaxoSmithKlineINDUSTRY | 2 | Nov 14, 2017 | clinicaltrials |
| NCT00849329 | A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer | completed | Phase 1 | 12 | GlaxoSmithKlineINDUSTRY | 3 | Nov 14, 2017 | clinicaltrials |
| NCT00861029 | VEG111485: A QTc Study of Pazopanib | completed | Phase 1 | 2 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT01231568 | An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor | completed | Phase 1 | 28 | GlaxoSmithKlineINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials